CalciMedica, Inc. Common Stock Net Assets
CalciMedica, Inc. Common Stock net assets. Based on the latest financial reports, CalciMedica, Inc. Common Stock (CALC) has net assets worth $-6.64 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($13.59 Million) and total liabilities ($20.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore CalciMedica, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.64 Million |
| % of Total Assets | -48.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | -110.21% |
| 10-Year Change | N/A |
| Growth Volatility | 135.66 |
Net Assets of CalciMedica, Inc. Common Stock (2018–2025)
Net assets of CalciMedica, Inc. Common Stock from 2018 to 2025. This chart illustrates how CalciMedica, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See net asset quality index of CalciMedica, Inc. Common Stock to measure how much of total assets are equity-financed.
Annual Net Assets for CalciMedica, Inc. Common Stock (2018–2025)
The table below shows the annual net assets of CalciMedica, Inc. Common Stock from 2018 to 2025. For live market cap and overall valuation, see CalciMedica, Inc. Common Stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-6.64 Million | -146.09% |
| 2024-12-31 | $14.41 Million | +76.66% |
| 2023-12-31 | $8.16 Million | +188.35% |
| 2022-12-31 | $-9.23 Million | -114.20% |
| 2021-12-31 | $65.02 Million | -31.40% |
| 2020-12-31 | $94.79 Million | +233.65% |
| 2019-12-31 | $28.41 Million | +136.37% |
| 2018-12-31 | $12.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CalciMedica, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12052700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
CalciMedica, Inc. Common Stock Net Assets Breakdown (December 2025)
CalciMedica, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | % |
| Other Components | $182.68 Million | % |
| Total Equity | $-6.64 Million | 100.00% |
CalciMedica, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of CalciMedica, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TWZ Corporation Public Company Limited
BK:TWZ
|
$9.90 Million |
|
Larq SA
WAR:LRQ
|
$9.91 Million |
|
Acme Holdings Bhd
KLSE:7131
|
$9.91 Million |
|
Medadvisor Ltd
AU:MDR
|
$9.91 Million |
|
TAG Oil Ltd.
V:TAO
|
$9.90 Million |
|
Meta Epsi Tbk PT
JK:MTPS
|
$9.90 Million |
|
Clean & Science co. Ltd
KQ:045520
|
$9.89 Million |
|
Techcential International Ltd
TWO:6616
|
$9.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CalciMedica, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 14,410,000 to -6,641,000, a change of -21,051,000 (-146.1%).
- Net loss of 29,562,000 reduced equity.
- New share issuances of 5,523,000 increased equity.
- Other comprehensive income decreased equity by 4,000.
- Other factors increased equity by 2,992,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-29.56 Million | -445.14% |
| Share Issuances | $5.52 Million | +83.17% |
| Other Comprehensive Income | $-4.00K | -0.06% |
| Other Changes | $2.99 Million | +45.05% |
| Total Change | $- | -146.09% |
Book Value vs Market Value Analysis
This analysis compares CalciMedica, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $14.02 | $1.46 | x |
| 2019-12-31 | $27.50 | $1.46 | x |
| 2020-12-31 | $200.50 | $1.46 | x |
| 2021-12-31 | $42.94 | $1.46 | x |
| 2022-12-31 | $-6.02 | $1.46 | x |
| 2023-12-31 | $1.82 | $1.46 | x |
| 2024-12-31 | $1.28 | $1.46 | x |
| 2025-12-31 | $0.00 | $1.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CalciMedica, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-120.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -236.11% | 0.00% | 0.00x | 1.48x | $-29.58 Million |
| 2019 | -130.37% | 0.00% | 0.00x | 1.43x | $-39.88 Million |
| 2020 | -29.05% | 0.00% | 0.00x | 1.07x | $-37.01 Million |
| 2021 | -55.09% | 0.00% | 0.00x | 1.06x | $-42.32 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.90 Million |
| 2023 | -421.20% | 0.00% | 0.00x | 1.49x | $-35.17 Million |
| 2024 | -95.07% | 0.00% | 0.00x | 1.37x | $-15.14 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.90 Million |
Industry Comparison
This section compares CalciMedica, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $126,960,080
- Average return on equity (ROE) among peers: -97.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CalciMedica, Inc. Common Stock (CALC) | $-6.64 Million | -236.11% | N/A | $9.90 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $15.18 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.55 Billion |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxi… Read more